Page 14 - Pharma Stocks
Cipla Q2 net profit seen rising 25% YoY; US sales may drop QoQ to $215 mn
Cipla Q2FY24 result preview: On a sequential basis (QoQ), Cipla's net profit is seen declining 1.1 per cent, while revenue may grow 2.2 per cent
 "Cipla Q2 net profit seen rising 25% YoY; US sales may drop QoQ to $215 mn")
Biocon slips 4% after USFDA asks for corrective measures at Malaysian unit
The USFDA has determined the inspection classification as 'OAI' (Official Action Indicated) post inspection of Biocon's step-down subsidiary in Malaysia.
 "Biocon slips 4% after USFDA asks for corrective measures at Malaysian unit")
Glenmark Pharma soars 10% after S&P Global upgrades outlook to positive
The rating agency expects Glenmark to significantly reduce debt on completion of the GLS sale and maintain healthy earnings.
 "Glenmark Pharma soars 10% after S&P Global upgrades outlook to positive")
Bajaj Healthcare zooms 53% in four weeks on healthy FY24 guidance
EBITDA margins would be in the range of 16 -20 per cent for the FY24, mainly driven by growth in the formulation biz and with the introduction of reverse engineering APIs launched in the last fiscal.
 "Bajaj Healthcare zooms 53% in four weeks on healthy FY24 guidance")
Lupin hits 2-year high on strong Q1 results; zooms 66% since April
With clearance of Pithampur Unit-2, the company expects to add product approvals for the US region
 "Lupin hits 2-year high on strong Q1 results; zooms 66% since April")
Cipla hits new high; up 6% on promoter stake sale buzz, strong Q1 results
With regards to the promoters stake sale buzz, the company said it will make appropriate disclosure in compliance with the Listing Regulations as and when any such requirement arises.
 "Cipla hits new high; up 6% on promoter stake sale buzz, strong Q1 results")
Sun Pharma Q1 profit may be weighed by weak US generic sales and Taro nos
Sun Pharma Q1 results: The company's Q1 net profit could dip fractionally by 0.15 per cent to Rs 2,058 crore against Rs 2,061 crore reported a year ago
 "Sun Pharma Q1 profit may be weighed by weak US generic sales and Taro nos")
Ajanta Pharma rallies 9%; hits record high on strong Q1 results
In past one week, the stock has surged 19 per cent and rallied nearly 40 per cent so far this calendar year.
 "Ajanta Pharma rallies 9%; hits record high on strong Q1 results")
Cipla surges 9% on strong Q1 results, raises FY24 margin guidance
For FY24, Cipla raised its EBITDA margin guidance to 23 per cent from 22 per cent earlier.
Cipla Q1 preview: India biz may push profit over 50% QoQ; US sales to drag
Cipla Q1 preview: The company's domestic business can grow 15 per cent quarter-on-quarter (QoQ), while US business could contract by up to 4 per cent QoQ to $195 million
 "Cipla Q1 preview: India biz may push profit over 50% QoQ; US sales to drag")
Dr Reddy's gains nearly 3% post completion of USFDA inspection at AP unit
The stock hit a fresh 52-week high at Rs 5,360, and has rallied over 19 per cent in less than two months.
 "Dr Reddy's gains nearly 3% post completion of USFDA inspection at AP unit")
Pharma stocks rally on lower price erosion, hopes of US generic mkt uptick
Pharma players with a major exposure to US mkt such as Sun Pharma, Lupin, Zydus Life, Dr Reddy's, Aurobindo, Torrent have been outperformers hitting their 52-week highs over the last couple of weeks
 "Pharma stocks rally on lower price erosion, hopes of US generic mkt uptick")
Spiriva approval gives earnings visibility to Lupin; valuations expensive
Lupin's shares declined 4.5 per cent in Thursday's intra-day trade
 "Spiriva approval gives earnings visibility to Lupin; valuations expensive")
Ajanta Pharma hits 52-week high on upbeat branded generic business outlook
The management is confident to scale up margins again in the coming years on the back of enhanced contribution from Branded Generics business and normalisation of freight costs
 "Ajanta Pharma hits 52-week high on upbeat branded generic business outlook")
Torrent Pharma surges 8%, hits record high post March quarter results
Torrent's branded generics business India continues to perform well with focus on curatio acquisition and focus on power brands besides consumer business foray.
 "Torrent Pharma surges 8%, hits record high post March quarter results")
Stock of this pharma company has plunged 80% from its record high level
Shares of Gland Pharma tumbled 19 per cent to hit a new low of Rs 872.10 in Monday's intra-day trade, in an otherwise firm market
 "Stock of this pharma company has plunged 80% from its record high level")
Gland Pharma tanks 20%, hits record low on weak Q4 results
Revenue declined 29% YoY due to lower offtake of the key products in developed as well as domestic markets and due to Production line shut down in Pashamylaram Penems facility due to line upgradation.
 "Gland Pharma tanks 20%, hits record low on weak Q4 results")
This smallcap pharma company has zoomed 44% in 3 days on strong Q4 results
Since February 2, 2023, the stock price of Neuland Labs more-than-doubled or zoomed 116 per cent from level of Rs 1,409.75
 "This smallcap pharma company has zoomed 44% in 3 days on strong Q4 results")
Lupin extends gain, hits 52-wk high post Q4 results; surges 20% in 1 month
Analysts believe the stock is factoring margin recovery and certain niche launches in the US.
Dr Reddy's Labs sinks 7% on disappointing Q4 operating performance
In Q4, the company's North America's revenue declined 17 per cent QoQ to Rs 2,530 crore, due to fluctuations in demand for new launches.
 "Dr Reddy's Labs sinks 7% on disappointing Q4 operating performance")
